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ABSTRACT 
The discovery that prolonged administration of interferon-alpha (a pro-
inflammatory cytokine) readily precipitates depressive symptoms has played a key 
role in development of the inflammation theory of major depressive disorder 
(MDD). However, it remains unclear whether the clinical phenotype of patients with 
inflammation-associated depression significantly overlaps with, or can be 
distinguished from that of patients with ‘idiopathic’ depression. Here we explored 
the Hamilton depression scale factor structure of 172 patients undergoing 
interferon-alpha treatment for hepatitis-C at the point of transition to a depressive 
episode of DSM IV defined major depression severity. The resulting factor 
structure was first compared with a model derived from 6 previous studies of 
‘idiopathic’ MDD (Cole et al., 2004). This confirmatory factor analysis revealed that 
the factor structure of HAMD scores in our interferon-alpha treated cohort did not 
plausibly fit that previously described for ‘idiopathic’ MDD. Instead, subsequent 
exploratory factor analysis revealed a distinct four factor model with a novel 
primary factor grouping cognitive symptoms of depression and anxiety (HAMD 
items 1, 2, 9, 10, 11, 15). The second sleep disorder factor (items 4, 5, 6) replicated 
previous findings in ‘idiopathic’ depression. A third and unique factor grouped 
somatic symptoms and function (items 7, 12, 13, 14 and item 1). The final factor 
(also common in idiopathic depression studies), grouped gastrointestinal 
symptoms and weight loss (items 12 and 16). Severe depression items (3, 8, and 
17) were excluded from analysis due to very low variance. At transition, interferon-
alpha induced major depressive episodes therefore appears to have more 
associated anxiety features that covary with depressed mood than classical or 
‘idiopathic’ MDD and a low likelihood of severe features such as suicidal ideation. 
Identification of this clinical phenotype may help identify patients with an 
inflammatory depression etiology and support the development of more effective 
and personalized therapies.  
1. INTRODUCTION 
 
1.1 Sustained exposure to the pro-inflammatory cytokine interferon-alpha often 
precipitates a depression-like syndrome that is commonly described as appearing 
clinically indistinguishable from depression of other causes or ‘idiopathic’ 
depression (Raison et al., 2010). The risk of developing this syndrome increases 
with interferon-alpha dose and duration, and it typically remits following interferon-
alpha withdrawal (Fritz-French & Tyor, 2012; Whale et al., 2015; Udina et al., 2016; 
Fialho et al. 2017). From meta-analysis of existing studies, at least 25% of those 
exposed to interferon-alpha develop a major depressive episode (MDE) within 6 
months. Those with female gender, low educational level, history of major 
depressive disorder (MDD) or other psychiatric disorder, high baseline levels of 
interleukin 6 or subthreshold depressive symptoms (including psychomotor 
retardation and somatic symptoms) appear more vulnerable to developing this 
(Udina et al., 2012; Whale et al., 2015). These findings, together with now 
overwhelming evidence of raised inflammatory markers in at least a sub-group of 
patients with ‘idiopathic’ MDD (Haapakoski et al., 2015), have provided powerful 
support for the inflammatory hypothesis of depression (Lotrich, 2015; Eyre et al., 
2014). However, many MDD patients show minimal or even no evidence of 
systemic inflammation (Miller and Raison 2016), indicating the likely existence of 
an etiological subgroup. Furthermore, recent evidence suggests that some classes 
of conventional anti-depressant medications, such as serotonin reuptake 
inhibitors, have less influence on inflammatory processes and poorer efficacy in 
inflammation- compared to non-inflammation-associated depression (Uher et al., 
2014; Fialho et al., 2016).  
  
1.2 Whether individuals with inflammation-associated depression also show a 
characteristic clinical phenotype is under investigation. Previous studies have 
demonstrated that at least in the early stages, interferon-alpha induced depression 
is dominated by symptoms of fatigue and reduced motivation (Capuron et al., 
2002; Dowell et al., 2016). It is unclear whether these detectable differences in 
clinical phenotype persist with more prolonged exposure to inflammation. Capuron 
et al. (2009) undertook a direct comparison of HAMD item scores in interferon-
alpha induced depression in a group of malignant melanoma patients (n=9), after 
an average of 7 weeks exposure, and an ‘idiopathic’ depressed patient group 
(n=28), finding significantly greater psychomotor retardation and weight loss 
scores in the interferon group, lower guilt scores and similar scores across 
depressed mood, anxiety and impaired activity.  Reduced psychomotor speed has 
also been associated with raised peripheral inflammatory markers in depressed 
patient samples (Goldsmith et al., 2016; Krogh et al., 2014; Chamberlain et al. 
2019).  Identification of such clinical features, particularly if they are divergent from 
non-inflammation-associated or ‘idiopathic’ depression, may support more 
effective targeting of antidepressant treatments, and the development of 
personalized treatment strategies (Bhattacharya et al., 2016).  
 
1.3 Here, we use confirmatory factor analysis to first identify whether the clinical 
phenotype of patients who developed a major depressive episode (MDE) during 
interferon-alpha based treatment for hepatitis-C was quantitatively different from 
published populations of patients with ‘idiopathic’ MDD. We based this analysis on 
scores from the 17-item Hamilton Depression Rating Scale (HAMD), one of the 
most commonly used clinical tools for identifying and grading depressive 
symptoms. If a plausible fit between factor structures of interferon-alpha induced 
and ‘idiopathic’ depression was not observed, we aimed to use a secondary 
exploratory factor analysis to further characterize the specific clinical features of 
interferon-alpha induced depression.  
 
2. MATERIALS AND METHODS 
2.1 The study was based on a prospectively recruited cohort of 466 patients who 
received interferon-alpha based treatment for Hepatitis-C. The cohort consisted 
of consecutive referrals to the hepatology department at Brighton and Sussex 
University Hospital (BSUH), Brighton UK, a large specialist regional center 
serving a population of 0.5 million. For further details of this cohort and earlier 
findings, please see Whale et al., 2015. All participants had a serologically 
confirmed diagnosis of hepatitis-C, were aged between 18 and 65 years 
inclusive, and initiated PEGylated interferon-2-alpha 180 μg weekly sub-
cutaneously and oral ribavirin 800-1200mg daily (depending on weight and HCV 
genotype) between May 2008 and April 2014. Study data from the first 24 weeks 
of treatment was considered, as all hepatitis-C genotypes were recommended to 
receive at least this period of PEGylated interferon-2-alpha treatment.  Ethical 
approval was attained through the Brighton East National Research Ethics 
Committee.  All participants gave written informed consent for inclusion in the 
study.  
 
2.2 Participants were assessed by one of two experienced specialist hepatology 
nurses (MJK and AXF) at baseline and then every four weeks after initiation of 
interferon-alpha treatment. At each assessment point, MDE clinical threshold was 
explored using the Structured Clinical Interview for DSM-IV (SCID-I) (First et al., 
1996), excluding criterion A12D concerning organic etiologies. Patients with a 
SCID-I derived baseline diagnosis of MDD or taking any antidepressant treatment 
prior to starting the interferon-alpha-based therapy were excluded. The 17-item 
HAMD was used to characterize discrete features of depression at each 
assessment point (Hamilton, 1960). All patients transitioning to SCID-I defined 
MDE were included in this study and their HAMD scores at the point of reaching 
the MDE threshold were entered into the subsequent factor analyses. Both 
specialist nurses were trained in use of the SCID-I and HAMD, including clinical 
case examples, to ensure between-rater reliability. Case discussions were held 
throughout the study including group scoring activities. All scores were reviewed 
by the study chief investigator (RW), a research psychiatrist. 
2.3 All analyses were conducted using R 3.4.4 (R CoreTeam 2018). Normality of 
HAMD item scores was explored using the Shapiro Wilk test. Multivariate normality 
was tested using the MVN package (Korkmaz, Goksuluk, and Zararsiz 2014). 
Confirmatory factor analysis was conducted using the lavaan package (Rosseel 
2012) and parallel analysis used the nFactors package (Raiche 2010). The four 
factor latent structure of HAMD scores described by Cole and Motivala (Cole et 
al., 2004) of individuals with ‘idiopathic’ DSM defined MDD was used as the MDD 
comparator group. This structure was itself derived from analysis of 6 previous 
studies with methodology reaching stringent predefined criteria, from a total of 14 
studies identified between 1967 and 2002. Fit indices reported include the root 
mean square error of approximation (RMSEA), and Bentler’s comparative fit index 
(CFI). 
2.4 If the HAMD data for our cohort did not fit the Cole and Motivala model on 
confirmatory factor analysis, we next aimed to perform an exploratory factor 
analysis on all 17 HAMD items to define the specific factor structure of the 
interferon-alpha induced depression sample, methodology as supported by 
Schmitt (2011). This analysis was conducted using the psych package (Revelle 
2018).  
 
3. RESULTS 
3.1 The study population consisted of 111 men and 61 women (total N=172) who 
transitioned to MDE within the study period. This represents a transition rate within 
the whole interferon-alpha exposed sample of 36.9%. Their mean age was 44.0 
years, range 20 to 66, and mean time to transition to MDD following initiation of 
interferon-alpha was 5.6 weeks, range 4 to 24 weeks. There were no missing 
HAMD item values in this sample. 
Table 1 shows summary statistics for each item of the HAMD. For most items 
scores were centered at around or below 2, the midpoint of the scale. Three items, 
3 (suicide), 8 (psychomotor retardation) and 17 (loss of insight) had both a median 
and 75th centile of 0 indicating that at least 75% of participants responded with a 0 
(out of 4). Items 2 (guilt), 9 (agitation), 12 (somatic GI), 15 (hypochondriasis) and 
16 (weight loss) had a 75th centile score of 1 indicating that at least 75% of 
participants responded with a 1 or lower (out of 4). At the other extreme, item 7 
(work and interests) had a median of 3 and a 75th centile of 4, indicating that at 
least 50% of participants responded with a 3 (out of 4) and at least 25% of 
participants responded with the maximum score of 4. The scale total scores ranged 
from 7 to 37, M = 19.6, 95% CI [18.6, 20.5]. 
 
HAMD 
item 
Item 
description 
(range) 
n Mean SD Median Min Max 25th 75th Skew Kurtosis 
1 
Depressed mood 
(0-4) 
172 2.006 1.017 2.0 0 4 1 3 0.154 -0.415 
2 
Guilt  
(0-4) 
172 0.767 0.847 1.0 0 3 0 1 0.686 -0.669 
3 
Suicide  
(0-4) 
172 0.273 0.693 0.0 0 3 0 0 2.831 7.579 
4 
Insomnia initial 
(0-2) 
172 1.366 0.709 1.5 0 2 1 2 -0.651 -0.809 
5 
Insomnia middle 
(0-2) 
172 1.366 0.725 2.0 0 2 1 2 -0.675 -0.848 
6 
Insomnia 
delayed (0-2) 
172 1.337 0.735 1.0 0 2 1 2 -0.528 -0.863 
7 
Work and 
interests (0-4) 
172 3.023 1.037 3.0 0 4 2 4 -0.922 0.055 
8 
Retardation  
(0-4) 
172 0.145 0.442 0.0 0 3 0 0 3.502 13.875 
9 
Agitation  
(0-4) 
172 0.727 0.872 0.5 0 4 0 1 1.079 0.637 
10 
Anxiety psychic 
(0-4) 
172 1.872 1.264 2.0 0 4 1 3 0.291 -1.084 
11 
Anxiety somatic 
(0-4) 
172 1.337 0.873 1.0 0 4 1 2 0.292 -0.106 
12 
Somatic GI  
(0-2) 
172 1.047 0.638 1.0 0 2 1 1 -0.039 -0.566 
13 
Somatic general 
(0-2) 
172 1.605 0.557 2.0 0 2 1 2 -1.020 0.010 
14 
Genital 
symptoms (0-2) 
172 1.238 0.792 1.0 0 2 1 2 -0.445 -1.283 
15 
Hypochondriasis 
(0-4) 
172 0.634 0.865 0.0 0 3 0 1 1.042 -0.144 
16 
Weight loss  
(0-2) 
172 0.750 0.803 1.0 0 2 0 1 0.476 -1.303 
17 
Insight  
(0-2) 
172 0.058 0.258 0.0 0 2 0 0 4.709 23.751 
 
Table 1. Hamilton Depression Rating Scale items, scored in a cohort of 
patients with DSM-IV defined major depressive episode (MDE) following 
interferon-alpha treatment (N=172). 
 
3.2 Confirmatory Factor Analysis 
Figure 1 shows the Cole and Motivala model as fitted to our data. In this model, 
depression is conceptualized as a higher order psychological construct made up 
of four subordinate constructs of core depression (core), insomnia, anxiety and 
visceral symptoms. Of note, in factor analysis each of these latent constructs is 
revealed through analysis of the co-variance of scores on individual items of the 
HAMD. The fit of this conceptual model to our current data indicates how well this 
model of idiopathic depression describes our sample of patients with interferon-
alpha induced MDE. The model significantly deviated from a perfect fit, robust χ2 
(115) = 264.59, p < 0.001. The robust CFI = 0.79 fell short of the recommended 
value of 0.9 (Bentler 1990) indicating a poor fit to the data. The robust RMSEA = 
0.09 (90% CI = 0.078, 0.108) similarly confirmed this finding (MacCallum, Browne, 
and Sugawara 1996). In short, the four-factor latent structure of idiopathic 
depression described by Cole et al. (2004) is not a good description of the clinical 
phenotype of depression experienced by patients with DSM-IV defined MDE 
following interferon-alpha treatment.  
 
 Figure 1. Confirmatory factor analysis of the 17 item Hamilton Depression 
Rating Scale (HAMD) in a sample of patients with interferon-alpha induced 
depression (items in squares), exploring goodness of fit with Cole and 
Motivala’s rationally derived model of ‘idiopathic’ depression consisting of 
four factors (in circles): core depression (core), insomnia, anxiety and 
visceral. Standardized coefficients are included for each path.  
 
3.3 Exploratory Factor Analysis on the interferon-alpha induced depression 
sample 
Given that the Cole and Motivala model was a poor fit within our sample, we next 
performed an exploratory factor analysis to establish a more appropriate  
description of interferon-alpha induced depression. Items with virtually no 
variance, and therefore little discriminatory value (3, 8 and 17), were excluded. 
Figure 2 shows the scree plot of these data. Its point of inflexion suggests the 
presence of 4 underlying factors. The plot also contains the curve of corresponding 
eigenvalues from randomly generated data from the same sized sample obtained 
from a parallel analysis (Horn, 1965). In this analysis the point at which the two 
curves diverge indicates the number of factors to be retained. Importantly, this 
again identified four discrete factors. In short, the experience of depression in 
patients with DSM-IV MDE following interferon-alpha treatment is best-described 
by clustering items on the HAMD into four factors. A factor analysis was then 
conducted that forced 4 factors to be extracted using the minimum residual solution 
(of note this approach is preferred when covariance matrices are not well 
behaved). The factor solution was rotated using direct oblimin. The fit of this 4-
factor model was acceptable, RMSEA = 0.059 (90% CI = 0.024, 0.082). 
 
Figure 2. Scree Plot of 17 item Hamilton Depression Rating Scale scores, 
along with eigenvalues for random samples of the same size as the 
observed data (computed as per Horn’s parallel analysis). Factors should 
be retained from the point at which the two lines deviate 
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Table 2 shows the pattern matrix with factor loadings greater than 0.2 in bold. Items 
loading highly on Factor 1 (17.2% of variance) represent cognitive symptoms of 
anxiety and depression: depressed mood (item 1), feelings of guilt (item 2), 
agitation (item 9), anxiety (items 10 and 11) and hypochondriasis (item 15). Factor 
2 (15.8% of variance) represents sleep difficulties (items 4 to 6). Factor 3 (10.2% 
of variance) clustered physical symptoms and function: work and activities (item 
7), somatic gastro-intestinal (item 12, which cross-loaded strongly with Factor 4), 
somatic general (item 13), genital symptoms (item14), alongside depressed mood 
(item 1). Factor 4 (5.1% of variance) clustered items relating to gastro-intestinal 
symptoms (item 12) and loss of weight (item 16). As such, the experience of 
depression in patients with DSM-IV defined MDE following interferon-alpha 
treatment is best-described in terms of symptoms clustered by anxiety/depression, 
sleep, somatic symptoms and daily activity, and weight loss. 
HAMD Factor 1 Factor 2 Factor 3 Factor 4 
Item 1 0.423 0.125 0.400 0.013 
Item 2 0.470 -0.093 0.120 -0.079 
Item 4 -0.010 0.786 -0.073 0.135 
Item 5 -0.032 0.939 -0.001 -0.037 
Item 6 0.086 0.791 0.060 -0.071 
Item 7 0.101 0.050 0.499 -0.082 
Item 9 0.459 -0.211 -0.190 -0.018 
Item 10 0.873 0.011 -0.008 0.042 
Item 11 0.782 0.061 0.011 -0.098 
Item 12 0.016 0.034 0.382 0.371 
Item 13 -0.067 0.031 0.639 0.017 
Item 14 0.002 -0.089 0.631 0.039 
Item 15 0.628 0.000 -0.005 0.167 
Item 16 0.024 -0.011 0.007 0.707 
 
 
Table 2.  Factor loadings from the pattern matrix of a four-factor exploratory 
factor analysis of Hamilton Depression Rating Scale (HAMD) items in a 
cohort of patients with interferon-alpha induced major depressive episode. 
Factor loadings greater than 0.2 are shown in bold. 
 
4. DISCUSSION 
4.1 The primary aim of this study was to quantitatively explore potential differences 
in the clinical phenotype of interferon-alpha induced and ‘idiopathic’ major 
depression using a factor analysis of HAMD item scores. Factor analysis provides 
a method for understanding how individual items cluster together and whether this 
clustering of clinical features matches that expected from a control sample. Direct 
HAMD item score comparison was not possible in the current study (as in Capuron 
et al. 2009, in a smaller sample). However, comparison with prior factor analyses 
of ‘idiopathic’ MDD populations allowed us to demonstrate that the factor structure 
of our large cohort of interferon-alpha induced depression in hepatitis-C is 
inconsistent with that described for ‘idiopathic’ MDD. Subsequent exploratory 
factor analysis revealed a tighter coupling of anxiety and core depressive 
symptoms than is typically described for idiopathic depression. 
4.1.1 The transition rate to MDE in our interferon-alpha exposed group is 
consistent with the existing literature (Udina et al., 2012; Udina et al., 2016). In our 
interferon cohort, HAMD items with very low variance related to the more severe 
symptoms of MDD, suicide (item 3) and loss of insight (item 17). Of note, these 
items (as well as psychomotor retardation which also had very low variance in our 
sample) have been individually excluded in previous studies of ’idiopathic’ MDD, 
but not as a group within a specific study (Cole et al. 2004). In previous studies of 
MDD, the suicide item typically clusters with ‘depressed mood’ (item 1), though 
this was not observed in our group. Capuron et al. (2009) similarly found low mean 
scores in guilt, suicide and agitation items in their interferon-alpha group. 
Interferon-alpha induced MDE therefore appears to have a low association with 
such severe depression symptoms, at least at the point of transition to depression. 
4.2 Exploratory factor analysis revealed a novel 4-factor structure for interferon-
alpha induced MDE. Two of these factors, (1) anxiety/depression and (3) somatic 
symptoms and daily activity are unique to this clinical sample in comparison with 
idiopathic MDD. In contrast, both the insomnia (2) and ‘anorexia’/weight loss (4) 
factors have previously been defined in idiopathic MDD (Marcos and Salamero 
1990, Cole and Motivala 2004 and Brown et al. 1995, Gibbons et al. 1993, 
Pancheri et al 2002 respectively). 
4.2.1 Interestingly, our factor 1 identified a co-variance in anxiety and depression 
symptoms in interferon-alpha induced depression that is not described in previous 
factor analyses of ‘idiopathic’ MDD. In other words, in idiopathic MDD, core mood 
and combined anxiety items do not typically show strong shared variance. 
However, this combination of core mood and anxiety symptoms does appear to be 
a specific feature of interferon-alpha induced MDE. Of note, items 1 and 10 
(depressed mood and ‘psychic’ anxiety) were amongst the highest scored items in 
our sample. It is possible that anxiety is a more prominent feature of hepatitis-C 
than other interferon-alpha exposed populations (e.g. malignant melanoma) or 
inflamed-depressed populations (Capuron et al., 2009; Constant et al., 2005). 
Hepatitis-C populations also have a greater likelihood of historical substance 
misuse, which may complicate factor analysis of symptoms in comparison to other 
clinical populations, including mood and anxiety items. Our earlier description of 
this cohort indicated a high rate of prior intravenous drug use (94%) but any recent 
substance use (alcohol or illicit drug) was an exclusion factor to initiating interferon-
alpha treatment (Whale et al., 2015). These issues would benefit from prospective 
comparison of clinical groups in future studies. 
4.2.2 A somatic symptom factor has been observed in most previous HAMD factor 
structures (though they do not typically show consistent HAMD item 
configurations). In our cohort, 5 items clustered in our somatic factor (Factor 3). 
Only two of these items (7 and 14) were included in the Cole and Motivala ‘visceral’ 
factor. Two of our additional somatic cluster items, 1 and 7 (depressed mood and 
work/interests), are combined within factors with other various items in 4 previous 
studies (Gibbons et al. 1993, Marcos and Salamero 1990, Onega and Abraham 
1997 and Pancheri et al. 2002). Thus, our factor 3 somatic items may relate more 
to a chronic hepatitis sample (particularly item 12, gastrointestinal somatic 
symptoms) rather than a mood disorder. This could be addressed in future studies 
comparing individuals with chronic hepatitis-C with and without MDE and those 
with inflammation associated MDE but not hepatitis. On a related note, use of the 
HAMD to assess a syndrome with important somatic aspects may miss relevant 
features, especially given the 0-2 point ratings of items 12, 13, 14 and 16. 
4.2.3 HAMD defined psychomotor retardation was not a clear feature of interferon-
alpha induced MDE in this study and was excluded from the exploratory analysis 
due to its very low variance. This conflicts with previous findings in smaller clinical 
samples (such as Capuron et al. 2009). This absence may be unique to a hepatitis-
C population or to a pre-existing chronic inflammatory state. Psychomotor 
retardation has also been reported as an early clinical manifestation of 
inflammation (Capuron et al., 2002; Dowell et al., 2016) which reduces over time. 
Supporting this, we have previously found in this cohort that psychomotor 
retardation scored prior to interferon-alpha exposure is a vulnerability factor to later 
MDE (Whale et al. 2015). The HAMD scale may equally not be adequately 
sensitive to identify more experimentally identified abnormalities in motor speed, 
as shown by Goldsmith et al. (2016) and Krogh et al. (2014). Chamberlain et al. 
(2019) however found association with HAMD item 8 and raised C-reactive protein 
in a sample of depressed patients and controls. Further study of mood and 
motor/cognitive assessment in varied clinical samples at different time points 
would be beneficial to clarify this.  
4.3 Concerning the mechanism by which interferon-alpha exposure induces this 
mood syndrome, a wide biological effect has been described. Firstly interferon-
alpha potently activates immune systems, as reflected particularly by increases 
in peripheral and brain IL6, IL1 and TNF-α (Maes, 2011; Myint et al., 2013; Hoyo-
Bacerra et al., 2014). These cytokines are notably raised in some individuals with 
‘idiopathic’ depression (Dowlati et al. 2010) and have been demonstrated to alter 
tetrahydrobiopterin expression, a co-factor involved in monoamine production. 
Endogenous interferon-alpha also mediates immune responses to pathogens 
and tumor cells (Hoyo-Bacerra et al., 2014). Secondly, interferon-alpha clearly 
induces alterations in tryptophan metabolism, stimulating indoleamine 2,3-
dioxygenase activity which reduces serotonin availability, enhances quinolonic 
acid (enhancing glutamate neurotransmission) and reduces  kynurenic acid 
levels, which combined have a direct neurotoxic effect and modulate monoamine 
release associated with mood disorder (Wohleb et al., 2016; Hepgul et al., 2016). 
Thirdly, interferon-alpha activates hypothalamic-pituitary-adrenal axis function, a 
key component of normal human physiological stress responses, and resultant 
glucocorticoid expression has immunomodulatory effects (Walker and Spencer 
2018). Fourthly effects compromising neuronal plasticity and survival are also 
observed via interferon-alpha influence on BDNF expression and apoptotic 
pathways (Hoyo-Bacerra et al., 2014). Lastly, brain imaging studies of the effect 
of induced inflammation and depression associated inflammation have also 
identified potential common structures, both cortical and subcortical, which may 
mediate depressive disorder, and developing imaging technology may aid to 
identify specific pathways of phenotypic expression of differing etiologies of such 
disorders (Harrison, 2017). Interferon-alpha exposure therefore appears to be a 
possible model for inflammation associated mood disorders and induces this 
illness through some common pathways identified in ‘idiopathic’ depression 
etiology. The factor analysis we describe suggests a differing depression 
phenotype in those with an interferon-alpha induced episode however.   
4.3.1 Established antidepressant treatments which influence monoamine 
neurotransmission, have demonstrated efficacy and safety in interferon-alpha 
induced MDE (Schaefer et al, 2012) although the earlier neurovegetative 
syndrome appears less responsive to such treatment (Capuron & Miller, 2004). 
Anti-inflammatory medications as antidepressants appear more likely to have 
efficacy in inflammation associated depression (Leonard, 2014; Swardfager et al., 
2016). Identification of potential clinical features of such an inflammation 
associated MDE is therefore of value in addition to inflammatory biomarkers to 
help direct the design of studies to explore optimal treatment strategies for this 
group.  
4.4 Combining the findings discussed, an interferon-alpha induced MDE appears 
most likely to have prominent clinical features of cognitive symptoms of anxiety 
('psychic') and depressed mood, alongside low scores in guilt, agitation, suicidal 
ideation and lack of insight items. The inclusion of prominent psychomotor 
retardation in an inflammatory depression syndrome appears likely (based on 
previous studies) but may be most identifiable early in the course of inflammation 
with specific psychomotor speed tasks. Sleep symptoms and weight loss appear 
to have no discriminatory value from ‘idiopathic’ MDD. Somatic features require 
further detailed exploration.  Prospective validation of this symptom group in a 
clinical depressed sample using sensitive inflammatory markers and subsequent 
evaluation of response to anti-inflammatory agents would be of value. 
4.5 A limitation of our method is that clinical depression features explored in the 
interferon-alpha induced group are predefined by features necessary for a SCID 
diagnosis of MDE, and other symptoms that may cluster around these. However, 
we were able to explore the relative contribution of these features. Other clinical 
components of an interferon-alpha induced depression syndrome or the behavioral 
phenotype of inflammation, particularly sub- threshold MDE features, may have 
been missed in this methodology. Time sensitive features of the syndrome, 
including the proposed early fatigue syndrome (Capuron et al, 2002) were not 
explored. Using time point of identification of transition to MDE may not represent 
peak depression severity following interferon-alpha administration and may bias 
HAMD item scores. Our previous findings however (Whale et al., 2015) indicate a 
rapid increase of HAMD score within the first 4 weeks and a plateau of severity 
from around 8 weeks. In this sample, mean time to transition was 5.6 weeks and 
by this point we would expect mean scores to be within approximately 3 HAMD 
points of peak, particularly considering the time requirement of 2 weeks of 
threshold symptoms to achieve MDE criteria. Whilst inclusion of somatic items in 
the HAMD scale benefits assessment of an inflammation related mood syndrome, 
these are measured crudely (as discussed above) and other clear mood 
associated features such as hopelessness and more detailed cognitive aspects 
leading to suicidality are neglected. The HAMD scale was initially chosen for our 
study to enable comparison with existing studies and for ease of clinical use but 
clearly only offers a superficial symptomatic assessment of a complex clinical 
disorder. Finding differences in depressed populations based on this scale is an 
important preliminary finding however. We were equally unable to explore mania-
related symptoms associated with interferon exposure in this study, as reported 
previously as a common consequence by Constant et al. (2005). It is possible that 
agitation, anxiety and insomnia items recorded by the HAMD correspond to such 
syndromes, although in our sample agitation and anxiety had greatest factor 
association with depressed mood and guilt. Of note, agitation scores were overall 
low in this sample. Including a mania score in a future exploratory factor analysis 
would be of interest. Development of a tool to more specifically identify 
inflammation associated depression is an important goal of such research and may 
be based on discriminatory HAMD items.  
 4.5.1 The accuracy of scoring the HAMD scale in a hepatitis-C clinic setting could 
also be questioned but raters were trained by a psychiatrist (RW) and scoring 
reliability exercises were regularly undertaken.  Our findings could be by chance 
or related to statistical artefact, as argued in previous factor analysis studies. 
However, we were careful to include a large enough sample size and use robustly 
argued and varied statistical methods to limit this possibility. We were able to 
compare our findings with a rigorously developed factor model, and the numerous 
well conducted factor studies that led to this model including large, varied clinical 
samples with age and gender mix of depressed patients. Clear differences from 
our cohort were consistently observed. These comparator groups may have 
included inflammation associated MDE although this is highly unlikely to be the 
case for the whole sample.  
4.6 To conclude, we demonstrate that our cohort of interferon-alpha induced MDD 
differs in HAMD factor structure from that previously reported in ‘idiopathic’ MDD 
studies and clarify further the nature of the anxiety and depression cognitive 
syndrome induced by interferon-alpha. Though developed in an interferon-alpha 
treated cohort we argue that interferon-alpha exposure is a possible model for a 
more general inflammatory state reported in some patients with MDD. These 
findings may serve to augment clinical identification of patients with a likely 
inflammatory depression etiology that may be more effectively treated with novel 
immunotherapeutic agents. 
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